Clal Biotechnology Industries Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was ILS 20.69 million compared to ILS 22.62 million a year ago. Revenue was ILS 54.57 million compared to ILS 24.47 million a year ago. Net loss was ILS 18.98 million compared to ILS 17.61 million a year ago. Basic loss per share from continuing operations was ILS 0.12 compared to ILS 0.11 a year ago. Diluted loss per share from continuing operations was ILS 0.12. For the nine months, sales was ILS 59.65 million compared to ILS 52.57 million a year ago. Revenue was ILS 116.02 million compared to ILS 117.99 million a year ago. Net loss was ILS 56.89 million compared to ILS 6.4 million a year ago. Basic loss per share from continuing operations was ILS 0.36 compared to ILS 0.04 a year ago.